Lymphoma hub
@lymphomahub.bsky.social
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia.
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
November 6, 2025 at 5:30 PM
Francesc Bosch discussed factors influencing the use of fixed-duration therapy for patients with CLL.
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Watch the full video here: https://loom.ly/29aw1Zs
#leusm #lymsm #MedNews #MedEd
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
October 17, 2025 at 1:31 PM
Charles Herbaux, University of Montpellier, discusses the 2L and 3L+ data from the randomized phase III STARGLO trial of Glofit-GemOx vs R-GemOx in patients with R/R DLBCL.
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd
Watch the full video here: https://loom.ly/FdLag2Q
#lymsm #lymphoma #MedNews #MedEd